Approval · Notice of Compliance 28217 · 2022
XATRAL: Notice of Compliance 28217
Issued May 18, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28217
- Date
- May 18, 2022
- Company
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- To remove the Package Insert.
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XATRAL | Not yet assigned | — |
Medicinal ingredients
- ALFUZOSIN HCL 10 MG per TAB